The 12 most common product-led growth mistakes and how to fix them for healthcare and life sciences in the United Kingdom

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the United Kingdom. In this market, UK buyers reward understatement, credible references, and a pitch that respects their time, so the way you install product-led growth has to be shaped to that reality from day one.

Every product-led growth failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.

Mistake one, the foundational one: bolting PLG onto a product that requires a demo to understand. Fix by naming an owner and writing kill criteria before you spend a dollar.

Mistake two: mistaking volume for progress. Fix by making self-serve activation to paid conversion the only weekly headline number.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the United Kingdom it is compounded by the fact that credibility and reference base, not tooling is what actually gates growth. Product-led growth is only useful here when it is pointed at both constraints at once.

Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.

Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.

Mistake five: ignoring the trigger. Product-led growth works when CAC collapses when the product qualifies for you; without a real trigger the model is guesswork.

Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.

Concretely for healthcare and life sciences in the United Kingdom: the healthcare teams that install this get past procurement instead of dying in it, and a single London-anchored win reshapes an entire year of UK pipeline. That is the reason it is worth installing product-led growth deliberately for this market rather than importing a playbook designed for somewhere else.